Clinical Trial Update: Anti-suicidal Effects of Buprenorphine In Depressed Individuals [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating buprenorphine for anti-suicidal effects in depressed individuals has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Suicidal Ideation

Drugs mentioned

• buprenorphine (buprenorphine)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Suicidal Ideation, Major Depressive Disorder | Phase 3 | Status: WITHDRAWN